...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Management and Research >Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma
【24h】

Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma

机译：淀粉样蛋白β（A4）前体蛋白质：用于复发性鼻咽癌的潜在生物标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Aim: Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Southern China, Southeast Asia. Radiotherapy is the main treatment for NPC. Still, about 20% of patients with NPC have a recurrence. No effective serum biomarkers are available for recurrent nasopharyngeal carcinoma (rNPC) to date. This study aimed to explore whether amyloid beta (A4) precursor protein (APP) might serve as a valuable diagnostic and prognostic biomarker for patients with rNPC. Methods: In a previous study, a tandem mass tag–based proteomic test was performed, which screened 59 differentially expressed proteins (DEPs) between nonrecurrent nasopharyngeal carcinoma (nrNPC) and rNPC. In this study, a protein–protein interaction was conducted to screen the key proteins among the 59 DEPs. APP was validated and evaluated by enzyme-linked immunosorbent assay in 70 serum samples [recurrence (n = 35) and no-recurrence (n = 35)]. Also, the receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of APP. Results: The area under the ROC curve was 0.666 (95% CI: 0.514–0.818, P = 0.044). The best cutoff point of the relative expression levels for APP was 1.23 (concentration = 16.95 ng/mL), at which the sensitivity was 55.2% and the specificity was 90.9%. Conclusion: The findings indicated that APP might be a valuable diagnostic and prognostic biomarker for patients with rNPC.
机译：背景和目的：鼻咽癌（NPC）是中国南部南亚最常见的癌症之一。放射疗法是NPC的主要处理。仍然，大约20％的NPC患者经常发生。迄今为止，没有有效的血清生物标志物可用于复发性鼻咽癌（RNPC）。本研究旨在探讨淀粉样蛋白β（A4）前体蛋白（APP）是否可以作为RNPC患者的有价值的诊断和预后生物标志物。方法：在先前的研究中，进行串联质量标签的蛋白质组学试验，该蛋白质组学试验筛选出在非血管鼻咽癌（NRNPC）和RNPC之间的59个差异表达的蛋白质（DEP）。在该研究中，进行蛋白质 - 蛋白质相互作用，以筛选59 deps中的关键蛋白。在70颗粒样品中通过酶联免疫吸附测定进行验证和评估应用[复发（n = 35）和无复发（n = 35）]。此外，绘制了接收器操作特征（ROC）曲线以评估应用程序的预测值。结果：ROC曲线下的面积为0.666（95％CI：0.514-0.818，P = 0.044）。应用的相对表达水平的最佳截止点为1.23（浓度= 16.95ng / ml），敏感性为55.2％，特异性为90.9％。结论：该研究结果表明，应用可能是RNPC患者的有价值的诊断和预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号